STME — StimCell Enegetics Income Statement
0.000.00%
- $7.57m
- $8.02m
Annual income statement for StimCell Enegetics, fiscal year end - May 31st, USD millions except per share, conversion factor applied.
2021 May 31st | 2022 May 31st | 2023 May 31st | 2024 May 31st | 2025 May 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.007 | 0.006 | 0.003 | 0 | 0 |
Cost of Revenue | |||||
Gross Profit | 0.004 | 0.004 | 0 | 0 | — |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 0.732 | 0.678 | 0.45 | 0.081 | 0.528 |
Operating Profit | -0.725 | -0.672 | -0.448 | -0.081 | -0.528 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -0.911 | -0.697 | -0.495 | -0.142 | -0.566 |
Net Income After Taxes | -0.911 | -0.697 | -0.495 | -0.142 | -0.566 |
Net Income Before Extraordinary Items | |||||
Net Income | -0.911 | -0.697 | -0.495 | -0.142 | -0.566 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.911 | -0.697 | -0.495 | -0.142 | -0.566 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.182 | -0.167 | -0.118 | -0.031 | -0.028 |